Session

PP 05 IBD (Posters)

VITAMIN D DEFICIENCY IS ASSOCIATED WITH POOR DISEASE OUTCOME UNDER ANTI-TNF THERAPY IN CHILDREN WITH IBD
VITAMIN D DEFICIENCY IS ASSOCIATED WITH POOR DISEASE OUTCOME UNDER ANTI-TNF THERAPY IN CHILDREN WITH IBD

PP 05 IBD (Posters)  et al.

GENERATION, CHARACTERIZATION AND SCREENING OF ENT001 A NEW THERAPEUTIC TOOL FOR IBD
GENERATION, CHARACTERIZATION AND SCREENING OF ENT001 A NEW THERAPEUTIC TOOL FOR IBD

PP 05 IBD (Posters)  et al.

ADHERENCE TO GUIDELINES AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE: AN AUSTRALIAN EXPERIENCE
ADHERENCE TO GUIDELINES AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE: AN AUSTRALIAN EXPERIENCE

PP 05 IBD (Posters)  et al.

ARTIFICIAL INTELLIGENCE IN THE DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASES AND IRRITABLE BOWEL SYNDROME
ARTIFICIAL INTELLIGENCE IN THE DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASES AND IRRITABLE BOWEL SYNDROME

PP 05 IBD (Posters)  et al.

FACTORS ASSOCIATED WITH ABDOMINAL PAIN IN PATIENTS WITH ULCERATIVE COLITIS
FACTORS ASSOCIATED WITH ABDOMINAL PAIN IN PATIENTS WITH ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

DUAL THERAPY WITH CAROTEGRAST (AJM300: ORAL Α4 INTEGRIN ANTAGONIST) AND BIOLOGICS FOR REFRACTORY ULCERATIVE COLITIS
DUAL THERAPY WITH CAROTEGRAST (AJM300: ORAL Α4 INTEGRIN ANTAGONIST) AND BIOLOGICS FOR REFRACTORY ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

EXPOSURE TO ANTI-TNFΑ AGENT IS ASSOCIATED WITH THE DEVELOPMENT OF AUTOIMMUNE DISEASE IN INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY
EXPOSURE TO ANTI-TNFΑ AGENT IS ASSOCIATED WITH THE DEVELOPMENT OF AUTOIMMUNE DISEASE IN INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY

PP 05 IBD (Posters)  et al.

TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
TREATMENT DISCONTINUATION DUE TO LACK OF EFFICACY DURING MAINTENANCE TREATMENT WITH INFLIXIMAB OR VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

PP 05 IBD (Posters)  et al.

COST AND CONVENIENCE: MAJOR DRIVERS OF PATIENT PREFERENCE ON ROUTE OF BIOLOGIC ADMINISTRATION
COST AND CONVENIENCE: MAJOR DRIVERS OF PATIENT PREFERENCE ON ROUTE OF BIOLOGIC ADMINISTRATION

PP 05 IBD (Posters)  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

PP 05 IBD (Posters)  et al.

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

PP 05 IBD (Posters)  et al.

INTESTINE-SPECIFIC DELETION OF TNK1 KINASE AMELIORATES COLITIS BY MODULATING MICROBIOTA COMPOSITION
INTESTINE-SPECIFIC DELETION OF TNK1 KINASE AMELIORATES COLITIS BY MODULATING MICROBIOTA COMPOSITION

PP 05 IBD (Posters)  et al.

ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY
ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY

PP 05 IBD (Posters)  et al.

PREVALENCE OF CMV INFECTION IN IBD PATIENTS : DEFINING PREVALENCE, CLINICAL PROFILE AND OUTCOMES IN OUR CLINICAL PRACTICE
PREVALENCE OF CMV INFECTION IN IBD PATIENTS : DEFINING PREVALENCE, CLINICAL PROFILE AND OUTCOMES IN OUR CLINICAL PRACTICE

PP 05 IBD (Posters)  et al.

EARLY LIFE EMULSIFIER EXPOSURE INDUCES DYSBIOSIS AND DEFECTIVE INTESTINAL BARRIER IN THE OFFSPRING
EARLY LIFE EMULSIFIER EXPOSURE INDUCES DYSBIOSIS AND DEFECTIVE INTESTINAL BARRIER IN THE OFFSPRING

PP 05 IBD (Posters)  et al.

SUSTAINABILITY OF BIOLOGIC TREATMENT IN PAEDIATRIC PATIENTS WITH CROHN’S DISEASE: ANALYSIS BASED ON THE CZECH NATIONAL REGISTRY
SUSTAINABILITY OF BIOLOGIC TREATMENT IN PAEDIATRIC PATIENTS WITH CROHN’S DISEASE: ANALYSIS BASED ON THE CZECH NATIONAL REGISTRY

PP 05 IBD (Posters)  et al.

RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE
RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE

PP 05 IBD (Posters)  et al.

HOW CAN WE PREDICT THE DEVELOPMENT OF ANTIBODIES TO INFLIXIMAB IN CROHN’S DISEASE?
HOW CAN WE PREDICT THE DEVELOPMENT OF ANTIBODIES TO INFLIXIMAB IN CROHN’S DISEASE?

PP 05 IBD (Posters)  et al.

CORRELATION OF CALPROTECTIN AND BOWEL ULTRASOUND IN INFLAMMATORY BOWEL DISEASE (IBD)
CORRELATION OF CALPROTECTIN AND BOWEL ULTRASOUND IN INFLAMMATORY BOWEL DISEASE (IBD)

PP 05 IBD (Posters)  et al.

ANTI-TNF MONITORING EXPERIENCE IN A 3RD LEVEL HOSPITAL IN LATIN AMERICA
ANTI-TNF MONITORING EXPERIENCE IN A 3RD LEVEL HOSPITAL IN LATIN AMERICA

PP 05 IBD (Posters)  et al.

Item 141 - 160 / 826
1 2 3 4 5 6 7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42